A new trading day began on Monday, with G1 Therapeutics Inc (NASDAQ: GTHX) stock price down -5.27% from the previous day of trading, before settling in for the closing price of $4.55. GTHX’s price has ranged from $1.08 to $5.00 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 18.67% over the last five years. Meanwhile, its annual earnings per share averaged 28.33%. With a float of $42.38 million, this company’s outstanding shares have now reached $51.93 million.
The firm has a total of 100 workers. Let’s measure their productivity.
G1 Therapeutics Inc (GTHX) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of G1 Therapeutics Inc is 18.81%, while institutional ownership is 24.16%. The most recent insider transaction that took place on Mar 18 ’24, was worth 19,752. In this transaction Chief Financial Officer of this company sold 6,547 shares at a rate of $3.02, taking the stock ownership to the 123,896 shares. Before that another transaction happened on Feb 12 ’24, when Company’s Chief Medical Officer sold 28,600 for $4.62, making the entire transaction worth $132,143. This insider now owns 169,938 shares in total.
G1 Therapeutics Inc (GTHX) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of 68.81 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 28.33% per share during the next fiscal year.
G1 Therapeutics Inc (NASDAQ: GTHX) Trading Performance Indicators
Here are G1 Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 3.45. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.73.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.95, a number that is poised to hit -0.20 in the next quarter and is forecasted to reach -0.28 in one year’s time.
Technical Analysis of G1 Therapeutics Inc (GTHX)
Analysing the last 5-days average volume posted by the [G1 Therapeutics Inc, GTHX], we can find that recorded value of 0.68 million was lower than the volume posted last year of 1.37 million. As of the previous 9 days, the stock’s Stochastic %D was 42.53%. Additionally, its Average True Range was 0.36.
During the past 100 days, G1 Therapeutics Inc’s (GTHX) raw stochastic average was set at 79.88%, which indicates a significant increase from 24.51% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 56.12% in the past 14 days, which was lower than the 184.05% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.71, while its 200-day Moving Average is $2.54. Now, the first resistance to watch is $4.55. This is followed by the second major resistance level at $4.80. The third major resistance level sits at $4.98. If the price goes on to break the first support level at $4.12, it is likely to go to the next support level at $3.94. Should the price break the second support level, the third support level stands at $3.69.
G1 Therapeutics Inc (NASDAQ: GTHX) Key Stats
With a market capitalization of 224.98 million, the company has a total of 52,199K Shares Outstanding. Currently, annual sales are 82,510 K while annual income is -47,970 K. The company’s previous quarter sales were 14,870 K while its latest quarter income was -10,880 K.
